JPMorgan has lowered its rating on Insulet Corp., shifting the insulin pump maker from Overweight to Neutral and cutting its price target to $152 from $275. The brokerage attributed the change to a slowdown in U.S. sales growth, rising attrition among Type 2 diabetes patients and a 2027 outlook the firm views as weaker than previously anticipated.
Despite Insulet reporting robust second-quarter results and improved profitability guidance, JPMorgan said the company no longer offers an attractive risk-reward profile. The bank highlighted several operational headwinds it expects could weigh on near-term momentum, including slower additions of new patients, higher attrition among Type 2 users and potential competition in the patch-pump segment.
As part of the reassessment, JPMorgan removed the stock from its Analyst Focus List. The firm also said management commentary around 2027 seemed optimistic, particularly managements expectations for organic sales growth in the U.S. and internationally. JPMorgan believes those targets do not sufficiently reflect continued deceleration in the business, mounting competitive pressures and reimbursement uncertainty.
JPMorgan revised its 2027 financial model, lowering revenue by 7.6% to $3.67 billion and trimming adjusted earnings per share by 8.8% to $7.62. Changes to the firms 2026 outlook were described as modest. The bank signaled that investors are likely to remain cautious until Insulet demonstrates that growth has stabilized and that management has reset earnings expectations accordingly.
The brokerage identified the U.S. Type 2 diabetes market as the most significant concern. Weakness in that segment prompted Insulet to reduce its 2026 organic sales growth outlook, according to JPMorgan. The bank noted that, while the company beat second-quarter expectations and offered improved profitability guidance, market attention is centered more on the slowing top line than on margin gains.
International performance, however, remains a bright spot. JPMorgan pointed to solid uptake of the Omnipod system overseas and expansion into markets such as Spain and Australia. Still, the firm assessed that these international gains are likely to be overshadowed by softer U.S. demand and intensifying competition expected to surface in 2027.
Bottom line: JPMorgan's downgrade and significant reduction in the price target reflect concerns that near-term deceleration in U.S. Type 2 patient growth, rising attrition and forthcoming competition will constrain Insulet's growth trajectory, even as international adoption of Omnipod remains strong.